ReachMD CME

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35993/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35992/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35990/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35989/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35988/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35987/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35986/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35985/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/Retina-Case-Review-Translating-the-Data-Into-Care/36108/ Wondering how your practice’s use of with next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits.

CME credits: 0.50 Valid until: 17-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/ This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety across hormone receptor–positive and triple-negative disease settings. The discussion contrasts molecular structures, dosing schedules, and toxicity profiles of each ADC, providing insight into their positioning in treatment algorithms. Practical strategies for therapy sequencing, patient selection, and shared decision-making are emphasized throughout.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-comparison-of-proms-and-how-to-use-them-in-clinical-practice-for-pah/33241/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-travel-with-pah-logistics-medications-oxygen-and-emergency-preparedness/33237/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.